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ABSTRACT
The expression and localization of the oncoprotein c-Myc is highly regulated at the level of transcription, 
mRNA transport, translation, as well as stability of the protein. We previously showed that Annexin A2 
(AnxA2) binds to a specific localization element in the 3ʹuntranslated region (UTR) of c-myc mRNA and is 
involved in its localization to the perinuclear region. In the present study, we demonstrate that AnxA2 
binds in a Ca2+-dependent manner to the internal ribosomal entry site (IRES) containing two pseudo- 
knots in the 5´UTR of the c-myc mRNA. Here, we employ an in vitro rabbit reticulocyte lysate system with 
chimeric c-myc reporter mRNAs to demonstrate that binding of AnxA2 to the c-myc IRES modulates the 
expression of c-Myc. Notably, we show that low levels of AnxA2 appear to increase, while high levels of 
AnxA2 inhibits translation of the chimeric mRNA. However, when both the AnxA2-binding site and the 
ribosomal docking site in the c-myc IRES are deleted, AnxA2 has no effect on the translation of the 
reporter mRNA. Forskolin-treatment of PC12 cells results in upregulation of Ser25 phosphorylated AnxA2 
expression while c-Myc expression is down-regulated. The effect of forskolin on c-Myc expression and 
the level of Ser25 phosphorylated AnxA2 was abolished in the presence of EGTA. These findings indicate 
that AnxA2 regulates both the transport and subsequent translation of the c-myc mRNA, possibly by 
silencing the mRNA during its transport. They also suggest that AnxA2 act as a switch to turn off the 
c-myc IRES activity in the presence of calcium.
Abbreviations: AnxA2, Annexin A2; β2–µglob, β2-microglobulin; cpm, counts per minute; hnRNP, 
heterogenous nuclear ribonucleoprotein; IRES, internal ribosomal entry site; ITAF, IRES trans-acting 
factor; MM, multiple myeloma; PABP, poly(A)-binding protein; PCBP, poly(rC) binding protein; PSF, 
PTB-associated splicing factor; PTB, polypyrimidine tract binding protein; RRL, rabbit reticulocyte lysate; 
UTR, untranslated region; YB, Y-box binding protein.
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1. Introduction
Annexin A2 (AnxA2) is a multi-functional and - 
compartmental protein with a variety of functions related to 
intercellular and intracellular communication via exosomes, 
cell proliferation, membrane-cytoskeleton interactions, endo- 
and exocytosis, as well as mRNA transport and translation [1– 
4]. The different functions of AnxA2 are modulated by its 
post-translational modifications [4]. Furthermore, the expres-
sion of AnxA2 is deregulated in several cancers. It is down- 
regulated in prostate cancer and overexpressed in a variety of 
cancers, including those of the pancreas, breast and brain 
(reviewed by [5–7]). Moreover, AnxA2 is specifically upregu-
lated in invasive and metastatic breast cancer cells, while 
poorly invasive cells express only low levels of the protein 
[8]. Furthermore, the protein has been associated with 
increased chemotherapy resistance [9].
We have previously demonstrated that AnxA2 acts as an 
mRNA-binding protein associated with a specific subpopula-
tion of mRNP complexes linked to the cytoskeleton [10–13]. 
In addition, we have mapped the mRNA-binding site of 
AnxA2 to specific amino acids in helices C-D of its domain 
IV [10], as well as identified the AnxA2-binding regions of the 
3´untranslated regions (UTRs) of anxA2 [11] and c-myc [12] 
mRNAs. Our initial experiments also indicated a putative 
AnxA2 binding-site in the c-myc 5ʹUTR. As AnxA2 binds to 
the c-myc mRNA [11,12,14], it is likely to participate in the 
regulation of the expression of the c-Myc protein at the level 
of mRNA transport [12] and/or translation.
The cellular proto-oncogene c-Myc encodes a basic helix- 
loop-helix transcription factor that acts in conjunction with 
its partner Max by binding to E-box DNA sequences 
(CACGTG). The c-Myc-Max heterodimers are activators of 
a critical set of target genes involved in cell proliferation, 
differentiation, and apoptosis [15,16]. Like AnxA2, deregu-
lated expression of c-myc mRNA is associated with a wide 
range of cancers and their resistance to chemotherapy [17]. 
Tumorigenesis involving c-Myc is best illustrated in the case 
of human Burkitt’s lymphoma, the most rapidly proliferating 
type of human tumour [18]. The reciprocal chromosomal 
translocation associated with this disease recombines c-myc 
in juxtaposition with regulatory elements of the immunoglo-
bulin heavy or light chain loci, leading to altered expression of 
c-Myc [18]. Furthermore, c-Myc overexpression in transgenic 
mice triggers tumour development [19], indicating that it 
affects control mechanisms that are necessary to prevent 
abnormal proliferation and differentiation. Increased expres-
sion of c-Myc protein is also associated with multiple mye-
loma (MM) and is observed in MM-derived cell-lines, which 
inhabit a C-U mutation in the region of c-myc mRNA 
thought to possess an internal ribosomal entry site (IRES) 
[20]. The same mutation was detected in 42% of the samples 
derived from the bone marrow of MM patients [21]. It was 
suggested that the mutation could result in an altered reper-
toire of proteins associated with the IRES, the so-called ITAFs 
(IRES trans-acting factors) [20]. Interestingly, AnxA2 is not 
expressed in at least two B-cell lymphoma cell lines [22].
The highly complex regulation of c-Myc expression is 
modulated by several signal transduction pathways at multiple 
levels, including transcription [15,16], translation [23] as well 
as stability of the mRNA [24] and protein [25]. The human 
c-myc gene is transcribed from no less than four alternative 
promoters, designated as P0, P1, P2 and P3. The P1 and P2 
promoters account for almost all of the cytoplasmic c-myc 
mRNA, with the minor promoters, P0 and P3, lying upstream 
and downstream of P1 and P2, respectively [26]. Both human 
and mouse c-myc mRNAs encode two protein products of 
different size, c-Myc1 and c-Myc2, translated from two dif-
ferent initiation codons (CUG and AUG), respectively. 
c-Myc2 is the predominant form, which is responsible for 
cell growth and proliferation, whereas c-Myc1 has been 
reported to inhibit cell growth in the absence of c-Myc2 
[27]. Thus, the two isoforms are presumably involved in the 
regulation of different subsets of genes. The complex regula-
tion of c-Myc expression depends on many different factors. 
For example, c-myc mRNA translation is regulated by the 
prevailing levels of the initiation factor eIF4E, which binds 
to the cap structure [28].
The regulation of c-myc mRNA transport and translation is 
complicated and involves both of its UTRs and protein fac-
tors. In general, the 3ʹUTR of an mRNA is involved in its 
localization and stability, while the 5ʹUTR modulates gene 
expression by influencing the initiation of translation. 
However, the two UTRs interact via proteins to modulate 
translation. Thus, both regions are controlled via their inter-
action with trans-acting RNA-binding factors. Such factors 
recognize specific structures or sequences (cis-acting ele-
ments), present mainly in the UTRs (reviewed by [29,30]). 
In addition, small RNA molecules known as microRNAs 
(miRNAs) and long non-coding RNAs (lncRNAs), compo-
nents of mRNP complexes, are implicated in the regulation of 
translation and mRNA transport. They are thought to repress 
translation by interacting with the 3ʹUTR of mRNA (reviewed 
by [30,31]). A stem-loop structure in the c-myc 3ʹUTR func-
tions as a localization signal and targets c-myc mRNA to the 
perinuclear region for translation on cytoskeletal-bound poly-
somes [32,33]. AnxA2 binds to this localization element in the 
c-myc 3ʹUTR [12].
The 5ʹUTR of c-myc mRNA is considerably longer than the 
majority of eukaryotic 5ʹUTRs and contains complex second-
ary structures suggesting strong regulation of the translation 
of the c-myc mRNA. The translation initiation of c-myc 
mRNA is a complex process, occurring by two different 
mechanisms [26,34]. When cap-dependent initiation is com-
promised, there is a shift to internal ribosomal entry site 
(IRES)-directed translation initiation [35,36]. The IRES in 
human c-myc mRNA is located upstream of the CUG start 
codon of c-Myc2. Hence, it is present in transcripts initiated 
from the P0, P1, and P2 promoters, and has the ability to 
promote cap-independent synthesis of both c-Myc isoforms 
(c-Myc1 and c-Myc2) [26,34]. However, at least in cells trans-
formed by eIF4E, there are indications of c-Myc1 being trans-
lated by ribosomal scanning from the cap structure, while 
c-Myc2 is translated by internal ribosome repositioning [37].
Several proteins (ITAFs) that interact with the c-myc IRES 
have been identified. It appears that the proteins involved in 
IRES-dependent translation initiation are regulated by their 
subcellular targeting and post-translational modifications 
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[38]. Canonical translation initiation factors are required for 
IRES-mediated translation, although the c-myc IRES functions 
in the absence of an eIF3-eIF4F interaction [39]. The c-myc 
IRES-mediated translation is stimulated by the poly(rC) bind-
ing proteins 1 and 2 (PCBP1 and PCBP2) and heterogeneous 
nuclear ribonucleoprotein K (hnRNP K) [40]. Interestingly, 
hnRNP K binds more strongly to the mutated IRES sequence 
found in MM, thus resulting in enhanced expression of c-Myc 
[40]. In addition, PCBP1, PCBP2 [41] and hnRNP K [42] are 
able to shuttle between the nucleus and the cytoplasm, indi-
cating that the proteins may interact with the c-myc IRES 
while still in the nucleus. Another protein, hnRNP C, binds 
specifically to a heptameric U sequence located between the 
two alternative translation initiation codons CUG and AUG 
in the 5ʹ-UTR of human c-myc mRNA [43]. At the G2/M 
phase of the cell cycle, the hnRNP C is especially enriched in 
the cytoplasm, giving rise to an increased translation of c-myc 
mRNA [43]. Moreover, hnRNP A1, G-rich RNA sequence 
binding factor 1 (GRSF-1), Y-box binding protein 1 (YB-1), 
polypyrimidine tract binding protein (PTB) as well as its 
associated splicing factor (PSF) and p54nrb (ligand of PSF) 
also bind to the c-myc IRES [44–46]. All these proteins sti-
mulate the translation of c-myc mRNA.
Fine-tuning of c-Myc expression is critical for key cellular 
functions, playing important roles in the regulation of growth, 
proliferation, differentiation, and apoptosis. Changes in 
c-Myc expression levels may shift its normal physiological 
role towards a pathophysiological role [47]. Therefore, eluci-
dating how the expression levels of c-Myc can be modulated is 
of great interest. Here, we employ an in vitro system with 
chimeric c-myc reporter mRNAs to demonstrate that binding 
of AnxA2 to the c-myc IRES modulates the expression of 
c-Myc.
2. Materials and methods
2.1 Recombinant Annexin A2
The bovine His-tagged AnxA2 (UniProtKB – P04272), the 
full-length non-RNA-binding mutant K307S-K308S-K309S- 
K312S-Y316S-Q320S AnxA2 [10] and the His-tagged 
N-terminally truncated forms of bovine AnxA2 (Δ19AnxA2; 
starts at Pro20 and Δ33AnxA2; starts at Ala34, counting the 
first Ser as 1) were expressed in E. coli and subsequently 
purified on Ni2+-resin (Ni-NTA agarose, Qiagen) essentially 
as described [11]. The His-maltose-binding protein (MBP)- 
AnxA2 (bovine), both wild type and the mutated form that 
does not bind RNA were also expressed and purified after 
tobacco etch virus (TEV) cleavage as described [10,11]. Note 
that wild type AnxA2 and mutated AnxA2 were not separated 
from His-MBP and His-TEV by using Q-Sepharose but were 
obtained by purification on a second Ni2+-affinity resin leav-
ing the His-tagged proteins bound to the resin. All recombi-
nant forms of AnxA2 were gel filtrated on a SuperdexTM 200 
Increase 10/300 GL column (GE Healthcare Bio-Sciences AB, 
Sweden). The purity of recombinant AnxA2 was determined 
by SDS-PAGE followed by Coomassie Brilliant Blue staining 
(InstantBlue, Abcam, Cambridge, UK). The NanoDrop quan-
titation method was employed for purified AnxA2 based on 
its Mw, extinction coefficient (33,810 M−1cm−1) and the 
absorption was measured at 280 nm.
2.2 Seamless cloning of the cDNAs coding for the 
different regions of the chimeric mRNAs
The BbsI restriction enzyme type two was used in the seamless 
cloning procedures [48] and was introduced in the primers used for 
seamless cloning (Table 1). It cleaves at N + 2 (3ʹend) and N + 6 
(5ʹend), counted from the last base of its recognition site. After PCR 
production of each of the cDNA fragments of the chimeric mRNAs 
and restriction enzyme digestion, the purified PCR fragments were 
ligated with T4 ligase. The DNA fragments were ligated in 
a stepwise manner (initially two fragments were ligated, then the 
third), and incubated 30 min each at RT. Finally, the vector was 
added, and the whole reaction was ligated ON at 4°C. The con-
structs were ligated into the EcoRI and XbaI sites of the pGEM®-3Zf 
(+) plasmid (Promega, Madison, USA) for storage. All constructs 
were sequenced in both directions to verify their orientation and 
sequences. The cDNAs used for the construction of the chimeric 
cDNAs were from the mouse c-myc (variant 2: NM_001177353.1) 
and the codon-optimized Renilla luciferase cDNA (a generous gift 
from Dr. Beate Stern, University of Bergen, Norway).
Table 1. Primers for seamless BbsI cloning (recognition site in bold) of the c-myc 
chimera 1A and the and β2-µglob chimera and subsequent synthesis of PCR 
products with T7 promoter.
DNA coding for Direction Primer Sequence






3ʹUTR of c-myc F 5´-ATCCGGGAAGACTT- 
GTAAACTGACCTAACTCGAGGAGG-3´
R 5´-GTATTTTTTCCAATTATTTT-3´










The deletion of regions 4A, 4B and 4 in the c-myc 5´UTR in the chimeric 
construct 1B, 1 C and 1D, respectively, were made with the following pair of 
primers: 
Deletion of region 4A: template; chimera 1A 
Forward primer: 5ʹ-ATCCGGGAAGACTTCAGAAACATCAGCGGCCGCAACCCTC 
Rev primer: 5ʹ-ATCCGGGAAGACTTTCTGTCTCTCGCTGGAATTACTACAGCGAGTCAG 
AAAAAAACGCC 
Deletion of region 4B: template; chimera 1A; partially overlapping primers on 
each side of the deletion 
Forward primer: 5´CGACTGACCCCACTTCTCACTGGAACTTACAATCTGCGAGCCAGG 
AC 
Rev primer: 5´GTGAGAAGTGGGGTCAGTCGCAGGGTTGGGGAGAGTGGGC 
Deletion of region 4: template c-myc chimeric construct without region 4A in the 
c-myc IRES 
Forward primer: 5ʹ-ATCCGGGAAGACTTCAGA-CACTTCTCACTGGAACTTACAATCTG 
CGAGCCAGG-3ʹ 
Rev primer: 5ʹ-ATCCGGGAAGACTTTCTGTCTCTCGCTGGAATTACTACAGCGAGTCAG 
AAAAAAACGCC 
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2.3 In vitro transcription
RNA probes were uniformly [α-32P] UTP-labelled (3000 Ci/ 
mmol; EasyTide, Waltham, PerkinElmer, USA) by T7-driven 
in vitro transcription of PCR products (Table 2) for 90 min, 
by standard procedures as described in the Promega protocol. 
A specific activity of 1.0–2.5 × 108 cpm/μg RNA was obtained. 
Primers for the different regions of the c-myc 5ʹUTR are given 
in Table 2. Labelled RNA probes were analysed for integrity 
and purity by agarose gel electrophoresis. Annealing of the 
NA and NB was performed by mixing the two transcripts at 
a 1:1 molar ratio in Binding Buffer (10 mM triethanolamine, 
pH 7.4 (Fluka, Thermo Fisher Scientific, Waltham, USA), 
50 mM KCl (Merck Millipore, Burlington, USA), 1 mM 
DTT (Sigma-Aldrich, Saint-Louis, USA), 2 mM MgSO4 
(Sigma-Aldrich, Saint-Louis, USA), 70 µM CaCl2 (Sigma- 
Aldrich, Saint-Louis, USA), 1 mg/mL yeast tRNA 
(Invitrogen, Thermo Fisher Scientific, Waltham, USA). 
Subsequently, the RNA probes were heated to 95°C for 
5 min and allowed to cool slowly to RT.
2.4 Capture of AnxA2 from the cytoskeletal fraction by 
in vitro transcribed c-myc 5´UTR with or without the IRES
The c-myc 5´UTR with or without the IRES (region 4) were 
in vitro transcribed from the corresponding PCR products 
containing a T7 promoter site using the HiScribe T7 High 
Yield RNA Synthesis Kit (New England BioLabs, Boston, 
USA) according to the manufacturer. The DNA template 
was removed by treatment with RQ1 RNase-free DNase 
(Promega, Madison, USA) for 15 min at 37°C. After phenol/ 
chloroform/isoamyl alcohol extraction and subsequent preci-
pitation with 3 M sodium acetate (pH 5.2; Thermo Fisher 
Scientific, Waltham, USA) and ethanol (Vinmonopolet, Oslo, 
Norway), purified RNA transcripts were resuspended in 
ddH2O after centrifugation at 16,000 g for 30 min and two 
washes with 70% (v/v) ethanol. An antisense biotin-5´DNA 
oligomer (5ʹ-CGTCGTGGCTGTCTGCGGGG-3ʹ) to the 3 
´end of the full-length c-myc 5´UTR as well as the c-myc 5 
´UTR lacking region 4 was bound to the PBS pre-washed 
streptavidin magnetic beads (50 µL) for 3 h at room tempera-
ture in PBS containing 1 M NaCl. After three washes of the 
coated beads in PBS, RNA transcripts (20 pmoles) were first 
heated to 72°C and then cooled slowly before incubation ON 
at 4°C with the biotin-5´DNA oligomer (Sigma-Aldrich, 
Saint-Louis, USA) coupled to the magnetic streptavidin 
beads (Dynal, Thermo Fisher Scientific, Waltham, USA) in 
130 mM KCl buffer (130 mM KCl, 5 mM MgSO4, 8.6% (w/v) 
sucrose, 10 mM triethanolamin; pH 7.4) containing RNasin 
(Promega, Madison, USA). Subsequently, the beads were 
washed twice in 130 mM KCl buffer and incubated with 
40 µg protein from the cytoskeletal fraction derived from 
PC12 cells in the same buffer prepared as previously described 
[49,50] for 3 h at RT in the presence of protease inhibitors 
(cOmplete EDTA-free; Roche, Basel, Switzerland) and RNasin 
(Promega, Madison, USA) in the absence or presence of 
EGTA or CaCl2 as indicated in Fig. 2. The coated beads 
were washed and incubated with RNase A/T1 mix (Thermo 
Fisher Scientific, Waltham, USA) for 40 min at 37°C to release 
the proteins associated with the RNA transcripts. The released 
proteins were concentrated by precipitation ON with 4x 
volume cold acetone at −20°C. The samples were centrifuged 
16,000 rpm x 30 min and the pellets were dried before resus-
pension in H2O and denaturation buffer. The samples were 
heated for 15 min at 56°C before SDS-PAGE and Western 
blot analyses.
2.5 Annexin A2-RNA binding
The interaction of AnxA2 with RNA was assayed by UV- 
crosslinking experiments, performed essentially as described 
[11]. RNA transcripts were preheated for 3 min at 72°C, and 
then gradually cooled for 15 min to RT to allow folding of 
secondary structures. AnxA2 and mRNA were incubated in 
Binding Buffer for 20 min at RT in solution before UV- 
crosslinking. After SDS-PAGE, proteins in the gels were 





(forward primers include T7 promotor)
∆1-517 c-myc 5′TAATACGACTCACTATAGG-ACCCCTGGCTGCGCTGCTCT (F)
5′GCTCTTTTCAGGAGAGCTGA (R)
∆1-127 c-myc 1 5′TAATACGACTCACTATAGGACCCCTGGCTGCGCTGCTCT(F)
5′ACTCAGGATCCCTCCCCTCC (R)
∆1-128-444 c-myc 2 5′TAATACGACTCACTATAGG-CGCAGTATAAAAGAAGCTTT (F)
5′GGAGCCTGGGGAGTCCTGTC (R)
∆445-517 c-myc 3 5′TAATACGACTCACTATAGG-GGGGAGGGAATTTTTGTCTAT (F)
5′GCTCTTTTCAGGAGAGCTGA (R)
∆196-393 c-myc 4 5′TAATACGACTCACTATAGG-GGGAGTGAGCGGACGGTTGG (F)
5′GTGTCTGCCCGCTGCAATGG (R)
∆196-331 c-myc 4A 5′TAATACGACTCACTATAGG-GGGAGTGAGCGGACGGTTGG (F)
5′GGGTCAGTCGCAGGGTTGGG (R)
∆238-290 c-myc 4Ai 5′TAATACGACTCACTATAGG-CGCTCCGGGGCGACCTAAGA (F)
5′GAGGCAAAGCCCCTCTCACT (R)
∆332-393 c-myc 4B 5′TAATACGACTCACTATAGG-AACATCAGCGGCCGCAACCC (F)
5′GTGTCTGCCCGCTGCAATGG (R)
∆1-127 c-myc NA 5′TAATACGACTCACTATAGG-CGCAGTATAAAAGAAGCTTT (F)
5′GGAGCCTGGGGAGTCCTGTC (R)
∆1-127 c-myc NB 5′TAATACGACTCACTATAGG-GGAGCCTGGGGAGTCCTGTC (F)
5′GGAGCCTGGGGAGTCCTGTC (R)
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stained by Coomassie Brilliant Blue. Subsequently, the gels 
were dried and exposed to screens.
2.6 In vitro coupled transcription-translation system
The TNT® T7 Quick for PCR DNA is an in vitro coupled 
transcription/translation system based on rabbit reticulocyte 
lysate (RRL) (Promega, Madison, USA). Prior to these assays, 
DNA templates were PCR amplified using forward primers 
containing a T7 promoter site. The primers were the same for 
all the four c-myc chimeric constructs: 5′-TAATACGAC 
TCACTATAGG-ACCCCTGGCTGCGCTGCTCT (5´UTR 
c-myc forward with a T7 promoter site) and 5ʹ-GTATTT 
TTTCCAATTATTTT (c-myc 3´UTR reverse). PCR products 
were subjected to agarose gel electrophoresis; bands of correct 
sizes were excised from the gel and purified.
The reaction mixture was incubated for 60 min at 30°C. 
Two parallels of 1 μL were spotted directly onto filter to 
measure the total radioactivity in the mixture. Two parallels 
were withdrawn for scintillation counting at 0, 15 and 30 min, 
while triplicates were withdrawn at 60 min and each aliquot 
was transferred into 1 mL of 1 M NaOH with 2% H2O2, which 
was subsequently incubated for 10 min at 37°C. After incuba-
tion, 2 mL of ice-cold 25% trichloroacetic acid (TCA) contain-
ing 2% (w/v) casein hydrolyzate (Sigma-Aldrich, Saint-Louis, 
USA) was added, and the samples were placed on ice for at 
least 30 min. The precipitate was filtrated on glass fibre filters 
and washed 7 times with 5% TCA. Subsequently, the filters 
were washed with 96% ethanol and 4 mL of scintillation liquid 
Figure 1. Annexin A2 binds to the c-myc IRES. Panel A: Schematic representation of the predicted secondary structure of mouse c-myc 5ʹUTR using Sfold and the 
different regions (transcripts) of c-myc 5ʹUTR used in the binding experiments. Panel B: Schematic representation of the locations of regions 4A, 4Ai and 4B of mouse 
c-myc IRES in the experimentally deduced human c-myc IRES (adopted from [53]). Panel C: The binding of different radiolabelled [α32P]-rUTP c-myc 5ʹUTR transcripts 
to 3 μM AnxA2 in the presence of 70 µM Ca2+. 15 fmoles of regions 1–4Ai and the stem region of region 2, consisting of NegA (NA) and NegB (NB), as indicated in 
Panel A, were UV-crosslinked with AnxA2. AnxA2 stained with Coomassie Brilliant Blue served as a loading control. Panel D: UV-crosslinking of 3 μM of recombinant 
AnxA2 bound to 20 fmoles of uniformly radiolabelled full-length c-myc 5´UTR transcript alone (lanes 2 and 5), and to increasing amounts (10- or 50-fold molar excess) 
of the unlabelled c-myc full-length 5´UTR (lanes 3 and 4, respectively), and region 4A of the 5´UTR (lanes 6 and 7, respectively). Lane 1 contained only the 
radiolabelled full-length c-myc 5´UTR transcript to assess the effect of the RNAses added after UV-exposure. AnxA2 stained with Coomassie Brilliant Blue served as 
a loading control. Note that the protein bands in the upper gel were slightly blurred during drying before exposure to screens and phosphor imaging. Panels C and 
D: The transcripts were covalently bound to AnxA2 in the presence of 1 μg/μL yeast tRNA to inhibit non-specific RNA binding and then subjected to 10% SDS-PAGE. 
The binding was visualized using screens and phosphor imaging after ON exposure. AnxA2 is indicated to the right. Panel E: Histogram of the results of the binding 
competition; UV-crosslinking of 3 μM of recombinant AnxA2 bound to 20 fmoles of uniformly radiolabelled full-length c-myc 5´UTR transcript alone (columns 1 
and 4), and to increasing amounts (10- or 50-fold molar excess) of the unlabelled c-myc full-length 5´UTR (columns 2 and 3, respectively), or region 4A of the 5´UTR 
(columns 5 and 6, respectively). The mean of two experiments is shown.
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Figure 2. AnxA2 derived from PC12 cells and wild type recombinant AnxA2 binds the IRES of c-myc 5´UTR in the presence of calcium. Panel A: Schematic 
presentation of the AnxA2 ‘capture’ procedure by the c-myc 5´UTR with or without the IRES as baits. An antisense biotin-5´DNA oligomer to the 3´end of c-myc 
5´UTR was bound to magnetic streptavidin beads. Subsequently, the c-myc 5´UTR with or without the IRES was bound to the immobilized antisense DNA oligomer. 
The now immobilized c-myc 5´UTRs were incubated with the cytoskeletal fraction of PC12 cells. After several washes, proteins were released by RNase A/T1 treatment 
before SDS-PAGE and Western blot analyses using AnxA2 monoclonal antibodies. Panel B: AnxA2 in the cytoskeletal fraction of PC12 cells binds to the c-myc 
5´UTR containing the IRES only in the presence of 70 µM Ca2+, but not to the c-myc 5´UTR lacking the IRES. The procedure was performed in the absence (lanes 1 
and 4) or presence of 70 µM added Ca2+ (lanes 2 and 5) or in the presence of 2 mM EGTA (lanes 3 and 6). Panel C: The corresponding fractions containing unbound 
AnxA2 (not bound to the immobilized c-myc 5´UTRs) to the fractions shown in Panel B. Panel D: Control experiments showing that AnxA2 fails to bind to the DNA 
linker with biotin or to streptavidin and that RNase treatment is required to release the captured AnxA2 (compare with Panel B). The first lane to the left contains 
40 µg of proteins from the cytoskeletal fraction of PC12 cells. Panel E: Ca2+-dependency of the binding of full-length AnxA2, but not of its N-terminally truncated or 
His-tagged versions, to the c-myc IRES. 15 fmoles of region 2 of c-myc 5ʹUTR (as indicated in Fig. 1, Panel A) were UV-crosslinked with full-length AnxA2 (lane 1), 
∆19AnxA2 (lane 2), ∆33AnxA2 (lane 3) or His-tagged AnxA2 (lane 4) in the absence or presence of 70 µM Ca2+ as indicated and subjected to 10% SDS-PAGE. The RNA 
transcripts containing [α32P]-rUTP were covalently bound to AnxA2 in the presence of 1 μg/μL yeast tRNA to inhibit non-specific RNA binding, subjected to 10% SDS- 
PAGE, whereafter the binding was visualized using screens and phosphor-imaging after a 13 h exposure (or 22 h exposure for the two lanes numbered 4). AnxA2 
stained with Coomassie Brilliant Blue served as a loading control. AnxA2 is indicated to the right.
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(Opti-Fluor, PerkinElmer, Waltham, USA) was added to the 
filters in scintillation vials. Incorporated [35S]-Met into the 
RLuc reporter and total radioactivity in the reaction mixture 
were measured in the liquid scintillation counter (Packard).
2.7 Cell cultures and drug treatments
The adherent sub-clone of rat pheochromocytoma (PC12) 
cells were maintained as described previously [51] in RPMI 
1640 medium (R-8758, Sigma-Aldrich, Saint-Louis, USA), 
with 10% (v/v) horse serum (PAA Laboratories GmbH, GE 
Healthcare, Chicago, USA), 5% (v/v) foetal bovine serum 
(F-9665, Sigma-Aldrich, Saint-Louis, USA), 100 units/ml 
penicillin, and 100 μg/mL streptomycin (P-0781; Sigma- 
Aldrich, Saint-Louis, USA) in a humidified 5% CO2 atmo-
sphere at 37°C . The cells were treated with 100 μM EGTA 
(E-4378; Sigma-Aldrich, Saint-Louis, USA) and/or 20 μM for-
skolin (344282; Sigma-Aldrich, Saint-Louis, USA) for 1 h or 
2 h, as indicated. Cells were briefly washed with PBS and lysed 
in Lysis buffer (50 mM Hepes, 150 mM NaCl, 1 mM EDTA, 
0.5% (w/v) NP-40, 1 mM dithiothreitol, 1 mM Na3VO4, 
1 mM NaF, and 1x EDTA-free protease inhibitor cocktail 
from Roche (11836170001; Roche, Basel, Switzerland).
2.8 SDS-PAGE and immunoblot analysis
Samples from lysates were heated at 70°C for 10 min in 
Laemmli sample buffer (Bio-Rad Laboratories, Hercules, 
USA) and resolved in 10% or 4–20% (w/v) SDS-PAGE gels. 
Proteins were transferred to nitrocellulose membranes (#162- 
0112; Bio-Rad Laboratories, Hercules, USA), which were then 
blocked with 5% (w/v) BSA, probed with antibodies and 
developed using enhanced chemiluminescence reagents 
(WesternBright Sirius, Advansta; San Jose, USA). The blots 
were imaged using Gel DOC XRS+ (Bio-Rad Laboratories, 
Hercules, USA) and densitometric analyses were performed 
with Image J software (NIH, Bethesda, USA). Blots treated 
with phospho-specific antibody were stripped with restore 
stripping buffer (21059; Thermo Fisher Scientific, Waltham, 
USA) as per manual instruction, blocked and re-probed with 
antibody recognizing total protein. Densitometric values were 
expressed per unit of protein applied to the gel lane. Proteins 
were normalized to loading control. Antibodies used for 
immunoblotting were as follows: Annexin AII (1:1000; 
610069; BD Biosciences, Franklin Lakes, USA), Annexin AII 
(pSer25) (1:1000; OAAF00618; Aviva Systems Biology, San 
Diego, USA), c-Fos (1:1000; PC-38; Merck Millipore, 
Burlington, USA), GAPDH (1:5000; 32233; Santa Cruz 
Biotechnology, Dallas, USA), c-Myc (1:1000; 32072; Abcam; 
Cambridge, UK), P-S133-CREB (1:1000; NB300-273; Novus 
Biologicals, Centennial, USA), p53 (1:1000; 263; Santa Cruz 
Biotechnology, Dallas, USA).
2.9 Statistical analysis
The arbitrary unit values are reported as mean ± SEM. 
Statistical comparisons were calculated with the student 
t-test using GraphPad Prism 9.0. Significance level was set at 
p < 0.05. Data correspond to representative of 3 or 4 inde-
pendent experiments.
3. Results
3.1 Annexin A2 binds to the IRES of the c-myc mRNA
We previously showed that AnxA2 interacts with the loca-
lization signal in the mouse c-myc 3ʹUTR [12]. Our pre-
vious UV-crosslinking experiments revealed that it may 
also bind to the c-myc 5ʹUTR, including both a 1–517 nt 
and a full-length 1–580 nt transcript of this region (data 
not shown). To identify the precise region of c-myc 5ʹUTR 
that interacts with AnxA2, we first used the Sfold platform 
(Wadsworth Bioinformatics Center, http://sfold.wadsworth. 
org/) to fold the mouse c-myc 5ʹUTR (1–517 nt) in silico 
into structures of predicted minimum free energy, ΔGo 
[52]. Consequently, the use of these proposed structures 
allowed the division of the 5ʹUTR (1–517 nt) into frag-
ments whose transcription would leave the originally pre-
dicted secondary structure of the c-myc 5ʹUTR (1–517 nt) 
as unperturbed as possible. Thus, radio-labelled region 1 
(1–127 nt; red), region 2 (128–444 nt; marked by black 
bar on top of the structure) and region 3 (445–517 nt; 
yellow) of c-myc were transcribed in vitro from the corre-
sponding PCR fragments containing a T7 promoter (Fig. 1, 
Panels A and B). When the binding of the transcripts to 
AnxA2 were tested in UV-crosslinking experiments, region 
2 was observed to bind AnxA2, while regions 1 and 3 failed 
to show binding (Fig. 1C). Subsequently, we generated 
radiolabelled RNA transcripts of subdomains of region 2. 
These included: region 4 (grey; 196–393 nt; consisting of 
regions 4A and 4B); the separate region 4A (196–331 nt; 
light blue) and region 4B (332–393 nt; purple) domains, as 
well as the 4Ai (238–290 nt; pink) domain. Additionally, we 
generated the stem region denoted NegA (NA; orange) and 
NegB (NB; green), corresponding to the lower part of 
region 2 (Fig. 1, Panels A and B). Interestingly, we found 
that AnxA2 preferentially binds to region 4A of the c-myc 
5ʹUTR (Fig. 1C). When comparing the regions of mouse 
c-myc 5ʹUTR (Fig. 1A) with those of human c-myc IRES 
(Fig. 1B)[53,54] by nt alignment, it was clear that the 
AnxA2-binding site in region 4A of c-myc 5ʹUTR is situated 
within the IRES. This site (region 4A) includes one side of 
the two pseudo-knots (Fig. 1, compare Panels A and B), 
while the other side is in region 4B. Region 4Ai contains 
only 2 nt at the 3ʹend of one of the pseudo-knots. It should 
be noted that when the two strands of the stem consisting 
of NegA and NegB were tested separately with AnxA2, 
a faint signal was observed, indicating weak interaction. 
However, when the double-stranded stem was tested with 
AnxA2, no binding was detected (Fig. 1C).
Subsequently, employing UV-crosslinking experiments, the 
binding of AnxA2 to full-length radiolabelled c-myc 5´UTR 
(Fig. 1D, lanes 2 and 5) was competed with 10x and 50x molar 
excess concentrations of unlabelled full-length c-myc 5´UTR 
(Fig. 1D, lanes 3 and 4) or region 4A of the IRES that binds 
AnxA2 (region Δ196-331 nt) (Fig. 1D, lanes 6 and 7), 
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respectively. These results (Fig. 1, Panels E and D) confirmed 
that AnxA2 binds to region 4A of the c-myc IRES.
3.2 The binding of Annexin A2 to the c-myc IRES is  
Ca2+-dependent
In vitro UV-crosslinking experiments showed that AnxA2 
binds to the IRES of c-myc 5´UTR (Fig. 1). To provide 
evidence that this interaction also takes place in vivo, we 
used in vitro transcribed full-length c-myc 5´UTR with the 
IRES to capture AnxA2 from the cytoskeletal fraction of PC12 
cells (Fig. 2) as we have previously shown that this fraction is 
enriched in AnxA2 [13]. In addition, equal pmoles of c-myc 
5´UTR without the IRES (without region 4) was used as 
a control (Fig. 2). By hybridizing the 3´end of the c-myc 
5´UTR to a biotinylated DNA oligomer, the 5´end was left 
free for interactions (Fig. 2A). Using this approach, we con-
firmed that AnxA2 binds to the c-myc IRES only in the 
presence of Ca2+ (Fig. 2B). It is also evident that there was 
considerably less AnxA2 left in the corresponding unbound 
fraction (not bound to the RNA transcript) than in the other 
two unbound fractions in which either no Ca2+ or EGTA was 
present during the ‘capture’ of AnxA2 from the cytoskeletal 
fraction of PC12 cells (Fig. 2C). Control experiments were 
also included, showing that AnxA2 does not interact with the 
biotin-5´DNA oligomer either in the absence or presence of 
Ca2+, and that RNase treatment is necessary to release the 
AnxA2 bound to the c-myc 5´UTR with the IRES (Fig. 2D). 
The latter property is a strong indication of its direct binding 
to the c-myc IRES (Fig. 2B). Only the c-myc 5´UTR was used 
in these assays since c-myc mRNA also contains an AnxA2- 
binding site in its 3´UTR [12]. Previously, AnxA2 pull-down 
experiments were performed by immunoprecipitating AnxA2 
followed by phenol extraction and precipitation of associated 
mRNAs. Subsequently, RT-PCR with specific primers showed 
that c-myc and anxA2 mRNAs are associated with the AnxA2 
protein, while the β2 – microglobulin (β2-µglob) mRNA is 
not [11].
The binding of AnxA2 to its cognate mRNA and the c-myc 
3ʹ- and 5´-UTRs is strictly Ca2+-dependent (Fig. 1 and Fig. 2, 
Panels B and C) [10–12]. This Ca2+-dependency has also been 
shown by others for the binding of AnxA2 to mRNA [14,55]. 
Calcium is only supposed to induce minor changes in the 
conformation of AnxA2 [1]. However, it renders the RNA- 
binding site accessible, possibly by changing the position of 
the first amino acids of the N-terminus of AnxA2 relative to 
the core structure, thus increasing the accessibility of amino 
acids in the RNA-binding site. To investigate the effect of 
AnxA2 on the translation of the chimeric c-myc reporter 
mRNAs, we wanted to use a lysate, the rabbit reticulocyte 
lysate (RRL), which has been used for numerous studies of 
translation. Due to the inclusion of Ca2+-dependent RNases in 
the commercial RRL, it was not possible to add exogenous 
Ca2+ to the reactions. To circumvent this problem, we used 
His-tagged AnxA2, which we found to bind RNA in the 
absence of Ca2+, most likely due to the exposure of its RNA- 
binding site (Fig. 2E, lane 4).
Normally, Pro21 is the first visible amino acid in the crystal 
structure [56], indicating that the most N-terminal part of the tail 
is unstructured and very flexible. Thus, we reasoned that if AnxA2 
would contain a His-tag, this would also render it able to bind 
RNA in a Ca2+-independent manner, as the presence of a longer 
tail would expose the RNA binding site – presumably by allowing 
greater flexibility and reducing the interaction of the N-terminus 
with the core structure. Indeed, this appears to be the case (Fig. 2E, 
lanes 4). Thus, the His-tagged AnxA2 may also be relevant in 
other assays, such as those related to AnxA2-actin interactions, 
which are Ca2+-dependent and involve domain IV of AnxA2.
Thus, taking into account that the mRNA-binding site of 
AnxA2 resides in its Domain IV [10], we produced three 
recombinant versions of the protein; a full-length AnxA2 
and two N-terminally truncated versions, namely, 
Δ19AnxA2 (devoid of the first 19 amino acids; counting the 
first Ser as amino acid no. 1) and Δ33AnxA2 (devoid of the 
first 33 amino acids). The Δ19AnxA2 form lacks the flexible 
part of the N-terminus, while Δ33AnxA2 lacks the entire 
N-terminus. The latter serves as a control, since it is folded, 
with the hypothesis being that part of the N-terminus of 
AnxA2 can render the RNA-binding site inaccessible in the 
absence of Ca2+. Accordingly, while full-length AnxA2 is 
unable to interact with region 2 of c-myc 5ʹUTR in the absence 
of Ca2+, both N-terminally truncated versions of AnxA2 show 
binding (Fig. 2).
3.3 Effect of the c-myc UTRs on translational efficiency 
of a chimeric reporter mRNA
It is well accepted that the 5ʹUTR interacts with the 3ʹUTR via 
specific proteins for efficient translation and that these 
dynamic interactions are highly regulated [57]. By lacking 
endogenous AnxA2, the RRL system for in vitro translation 
provides an ideal system, since it allows precise control of the 
concentration of exogenously added AnxA2. Therefore, we 
employed the coupled transcription/ translation RRL system 
to direct T7-driven expression of chimeric c-myc mRNAs 
from PCR products to investigate the effect of the c-myc 
UTRs on translation. To analyse the effect of c-myc UTRs 
on the efficiency of the translation of the reporter, Renilla 
luciferase (Rluc), six different chimeric mRNAs were pro-
duced containing no or different combinations of the 
5ʹUTRs (1–580 nt) and 3´UTRs of c-myc and/or β2- 
microglobulin (β2-µglob) mRNAs as indicated in Fig. 3A. 
This resulted in the following cDNAs: i) the coding region 
of the reporter, RLuc, alone, ii) c-myc-5ʹUTR-RLuc-c-myc- 
3ʹUTR (chimera 1A), iii) c-myc-5ʹUTR-RLuc (chimera 2), iv) 
RLuc-c-myc-3ʹUTR (chimera 3), v) β2-µglob-5ʹUTR-RLuc-β2 
-µglob-3ʹUTR (chimera 4) and vi) β2-µglob-5ʹUTR-RLuc 
-c-myc-3ʹUTR (chimera 5) (Fig. 3A). The latter contains 
a short 54 nt 5ʹUTR with the nucleotide sequence: 5ʹ-GATT 
TTCAGTGGCTGCTACTCGGCGCTTCAGTCGCGGTCGC-
TTCAGTCGTCAGC. It should be noted that we have pre-
viously shown that the β2-µglob-mRNA is not associated with 
AnxA2 using IP of AnxA2 and RT-PCR of immunoprecipi-
tated AnxA2 [11]. The T7-driven expression of the RLuc 
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reporter was performed in the RRL in vitro coupled transcrip-
tion/translation system and measured as the amount of [35S]- 
Met incorporated into the reporter protein. This translational 
system is a very sensitive and established approach.
The c-myc-5ʹUTR-RLuc-c-myc-3ʹUTR (chimera 1A) shows the 
highest translational efficiency (defined as 100%); while the coding 
region of RLuc alone has the lowest translational efficiency (Fig. 3B, 
compare chimera 1A with RLuc). Providing RLuc with the UTRs 
derived from the β2-µglobulin mRNA increases the translational 
efficiency about 2-fold (Fig. 3, compare RLuc with chimera 4). 
Exchanging the β2-µglob 3´UTR with that of c-myc 3´UTR has 
no effect on translational efficiency of the reporter (Fig. 3, compare 
chimera 4 with chimera 5). However, when RLuc is equipped with 
the c-myc UTRs, translational efficiency is changed dramatically 
(Fig. 3, compare chimera 1A with RLuc and chimera 4). 
Exchanging the c-myc 5ʹUTR with the β2-µglob 5ʹUTR decreases 
translational efficiency by more than 50% (Fig. 3, compare chimera 
1A with chimera 5) indicating specific crosstalk between the c-myc 
5ʹUTR and 3ʹUTR, presumably via protein interactions. This is 
corroborated by the results showing that the chimeric c-myc 
mRNA containing a c-myc 5ʹUTR, but no c-myc 3ʹUTR, also 
greatly diminishes the translation of the reporter (Fig. 3, compare 
chimera 1A with chimera 2), while the absence of a 5ʹUTR, as 
expected, also has an inhibitory effect on the efficiency of transla-
tion (Fig. 3, compare chimera 1A with chimera 3).
3.4 High concentrations of Annexin A2 inhibit 
translation of the chimeric reporter mRNA
The effect of AnxA2 on the T7-driven expression of the 
RLuc reporter in the RRL system was studied in the 
absence or presence of 10 or 20 μM AnxA2 using four 
different chimeric mRNAs, all coding for the reporter 
RLuc and full-length c-myc 3ʹUTR. In addition, chimera 
1A contains full-length 5ʹUTR, while chimera 1B contains 
the 5ʹUTR without region 4A (196–331 nt), chimera 1 C 
contains the 5ʹUTR without region 4B (331–393 nt) and 
chimera 1D contains the 5ʹUTR without region 4 (196–393 
nt) of c-myc mRNA (depicted in Fig. 4, Panels A-D). 
Quantitation of the expression after 60 min incubation 
was carried out by scintillation counting of the incorpora-
tion of [35S]-Met into the RLuc reporter protein (Fig. 4, 
Panels E-H, M and N).
The presence of AnxA2 in the RRL system significantly reduced 
the expression of the reporter protein from chimeras 1A (full-lengt 
c-myc 5´UTR), 1B (lacking region 4A) and 1C (lacking region 4B) 
(Fig. 4, Panels E, F, and G as well as Panels I, J, and K). Apparently, 
the translational inhibition by AnxA2 is less in the case of chimera 
1B, at least at higher concentrations of the protein (Fig. 4). 
Strikingly, AnxA2 had little or no effect on the expression of 
RLuc from the c-myc chimeric mRNA lacking region 4 (chimera 
1C), that is, lacking the two intact pseudo-knots as well as the 
ribosomal docking site (Fig. 4, Panels H and L).
Next, we analysed the kinetics of translation of the four 
chimeric mRNAs (Fig. 4, Panels I-L). Deleting region 4A of 
the c-myc IRES (chimera 1B) had little effect on the kinetics of 
translation, as compared to the chimeric mRNA containing 
full-length c-myc UTRs (chimera 1A) (Fig. 4, compare Panels 
E and F). However, when both region 4A and the ribosomal 
docking site (region 4B) – which together form region 4 (see 
Fig. 1) – were deleted, translation proceeded rapidly until 
30 min, but never reached the same efficiency as when using 
the two other chimeric mRNAs (Fig. 4, compare Panel L with 
Panels I and J). Noticeably, chimera 1C lacking the ribosomal 
docking site follows the same kinetics of translation as chi-
mera 1D (Fig. 4, compare Panels K and L) and has a much 
lower translational efficiency in the RRL than the other c-myc 
chimeras (Fig. 4, Panel M). Several control experiments were 
performed: A mutated AnxA2 that does not bind RNA [11,58] 
and bovine serum album (BSA) that has no effect on the 
translation of the chimeric mRNA containing full-length 
c-myc UTRs (chimera 1A) (Fig. 4N). Furthermore, no binding 
of AnxA2 to the coding region of the reporter RLuc was 
observed (Fig. 4O).
Figure 3. High translational efficiency of the chimeric c-myc reporter mRNA in an in vitro coupled transcription/translation system depends on the joint 
presence of the c-myc 5ʹUTR and 3ʹUTR. Panel A: Schematic representation of the different chimeric mRNAs used in Panel B: The T7-driven expression of chimeric 
mRNAs from PCR products (8 ng/μL) containing regions coding for the CDS of RLuc alone, c-myc-5ʹUTR-RLuc-c-myc-3ʹUTR (chimera 1A), c-myc-5ʹUTR-RLuc (chimera 
2), RLuc-c-myc-3ʹUTR (chimera 3), β2-µglob-5ʹUTR-RLuc-β2-µglob-3ʹUTR (chimera 4) or β2-µglob-5ʹUTR-RLuc-c-myc-3ʹUTR (chimera 5) mRNAs. The transcription 
reaction and subsequent translation of the RLuc reporter were performed at 30°C. The incorporation of [35S]-Met is expressed as the % relative to c-myc-5ʹUTR-RLuc 
-c-myc-3ʹUTR (chimera 1A; 100%). It was measured as counts per minute (cpm)/mole cDNA and determined using the mean value of the triplicates withdrawn at 
60 min to indicate the efficiency of each chimeric mRNA in the in vitro system. * Indicates p < 0.05 based on two-tailed Student’s t-test compared to control (RLuc 
alone).
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Figure 4. The effect of AnxA2 on the expression of the RLuc reporter in an in vitro coupled transcription/translation system. The T7-driven transcription of 
chimeric mRNAs from PCR fragments (22 ng/μL) containing the following coding regions: Panels E and I: chimera 1A [c-myc-5ʹUTR-RLuc-c-myc-3ʹUTR, as presented in 
Panel A]; Panels F and J: chimera 1B [presented in Panel B], Panels G and K: chimera 1 C [presented in Panel C] and Panels H and L [presented in Panel D]. Panels E, 
F, G and H: Translation for 60 min. The results are presented as percentage incorporated [35S]-Met, as determined by scintillation counting, relative to the reactions in 
the absence of His-AnxA2. Panels I, J, K and L: The equivalent time-course of the expression of the RLuc reporter in the in vitro coupled transcription/translation 
system to Panels E-H. Panel M: comparison of the relative translational efficiency of chimeras 1A, 1B, 1C and 1D [chimera 1A was set to 100%]. Panel N: Controls 
addressing the effects of 10 (blue columns) or 20 (orange columns) μM of exogenously added mutant AnxA2 that does not bind RNA [10,58] (dark blue and dark 
orange columns, respectively), or BSA (light blue and light orange columns, respectively), on the expression of chimera 1A were studied. The translation of the 
constructs was performed for 60 min at 30°C in the absence (green) or presence of 10 (blue) or 20 µM (orange) of His-AnxA2 as indicated. Aliquots in duplicates (0, 
15, and 30 min) or triplicates (60 min) were withdrawn and the incorporation of [35S]-Met, expressed as cpm/22 ng cDNA, is given as the mean value determined for 
the duplicates or triplicates. The standard deviations are also indicated. The results from three independent experiments (n = 3) are shown in % relative to control 
with no additions (100%) and the columns also indicate the standard deviations. Statistical significance was determined by the two-tailed Student’s t-test (*p < 0.05; 
n = 3). Panel O: The binding of radiolabelled [α32P]-rUTP transcripts to AnxA2. 15 fmoles of full-length 5ʹUTR (lane 1), 3ʹUTR (lane 2) of c-myc mRNA or CDS of hRLuc 
mRNA (lane 3) were UV-crosslinked with 3 μM of purified wt AnxA2 and subjected to 10% SDS-PAGE. The RNA containing [α32P]-rUTP and covalently bound to AnxA2 
was visualized using screens and phosphor-imaging following an ON exposure.
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3.5 Low concentrations of Annexin A2 appear to 
stimulate the translation of c-myc IRES-containing 
chimeric mRNA
AnxA2 is an abundant protein in many cell types. Serum 
levels of AnxA2 vary between 12–148 µg/mL (0.3–4 µM) in 
healthy humans and between 12 and 547 µg/mL (0.3–14 µM) 
in pancreatic cancer patients [59]. However, a literature 
search did not yield information on the actual molar concen-
tration of AnxA2 in cells. To investigate whether the tested 
concentrations of AnxA2 used in the in vitro system (Fig. 4) 
would be relevant in a physiological setting, we estimated the 
approximate concentration of AnxA2 in PC12 cells. Thus, 
using Western blot analysis we compared 30 µg and 60 µg 
of a whole cell lysate (612 µg total protein derived from 
4 × 106 PC12 cells as determined by IR spectroscopy) with 
0.1, 0.2, 0.5, 0.75, 1.0, 2.0 µg recombinant AnxA2. We found 
that 4 × 106 PC12 cells contain approximately 0.350 µg of 
AnxA2, corresponding to about 90 fg AnxA2/cell. The typical 
volume of mammalian cells is roughly 2000 µm3 (http://book. 
bionumbers.org/how-big-is-a-human-cell/). However, the 
PC12 cells with a diameter of 10–12 µm (https://bionum 
bers.hms.harvard.edu/bionumber.aspx?s=n&v=2&id=112695) 
are much smaller. They can be regarded as half spheres in 
culture (1/2 x (v = 4/3 πr3), giving an estimated volume of 
about 260–450 µm3. Therefore, the average concentration of 
AnxA2 in these cells is about 90 fg/39,000 Dalton = 0.0023 
fmoles as the molecular weight of AnxA2 is about 39 kDa, 
which sets its average concentration in PC12 cells at about 6– 
7 µM. Stimulation of PC12 cells with NGF induces a 3- to 14- 
fold increase in the level of AnxA2 protein [60,61]. Thus, in 
response to NGF stimulation the level of AnxA2 in PC12 cells 
would reach the concentration range that exerts an inhibitory 
effect on IRES-containing c-myc mRNA. To investigate if 
lower concentrations of AnxA2 inhibit the translation of 
c-myc mRNA in a dose-dependent manner, we investigated 
the effect of 0.1 µM and 1 µM AnxA2 on the expression of the 
reporter protein translated from the full-length c-myc chi-
meric mRNA (Fig. 5). Much to our surprise, we observed 
that AnxA2 at low concentrations appears to exert a low 
stimulatory effect on the translation of the reporter mRNA 
containing the c-myc UTRs. Apparently, the transition 
between the stimulatory and inhibitory translational effects 
of AnxA2 lies between 1 µM and 10 µM. According to our 
rough calculations on the average concentration of AnxA2 in 
the PC12 cells, these concentrations lie within the physiologi-
cally relevant AnxA2 concentrations. In addition, local differ-
ences in subcellular AnxA2 levels may be relevant, as well as 
local concentrations of specific AnxA2-binding mRNAs. Most 
likely, cellular feed-back mechanisms are also in action.
3.6 Forskolin treatment of PC12 cells decreases the 
expression of c-Myc
Having established that both recombinant and endogenous 
AnxA2 bind to the IRES of c-myc mRNA in a Ca2+-dependent 
manner and that AnxA2 modulates the expression of c-Myc 
in in vitro experiments, we next wanted to investigate if this is 
a physiologically relevant event in cells. Thus, AnxA2 would 
be expected to inhibit the translation of the c-myc mRNA at 
higher levels of Ca2+. Forskolin (Fsk) increases intracellular 
Ca2+ via regulating L-type calcium channel activities and the 
concentration of cyclic adenosine monophosphate (cAMP) 
[62]. Short-term (1 hr) treatment with Fsk was therefore 
used to increase the intracellular Ca2+ concentration to 
study the effect of Ca2+ on the expression of AnxA2 and 
c-Myc (Fig. 6). Furthermore, prior to stimulation with Fsk, 
pre-treatment with EGTA was performed to chelate Ca2+ and 
thus abolish the effects of this compound (Fig. 6). While such 
a short treatment appears to increase slightly the expression of 
AnxA2, the expression of c-Myc was reduced and importantly 
this effect was abolished when Ca2+ was chelated (Fig. 6, 
Panels A and B). As it has previously been shown that the 
Ca2+-dependent binding of AnxA2 to the IRES of p53 mRNA 
increases the expression of the corresponding protein [55], we 
also investigated the effect of Fsk on the expression of p53 in 
PC12 cells. As expected, Fsk resulted in an increase in the 
expression of p53, which was abolished by EGTA (Fig. 6, 
Panels A and B). We also verified that the pre-treatment 
alone with EGTA did not change the expression levels of 
AnxA2, c-Myc or p53 (data not shown). To confirm the 
specificity of the effect of Fsk, we examined the responsive-
ness of known Fsk targets in our experimental conditions 
(Fig. 6C). The phosphorylation of CREB showed robust 
enhancement after Fsk stimulation [63]. Furthermore, there 
was an increased expression of c-Fos [64]. In addition, Fsk 
treatment caused an increase in the level of Ser25 phosphory-
lated AnxA2, which was even more prominent after 2 hr 
exposure (Fig. 6D). This effect could be abolished by chelating 
Ca2+, indicating Ca2+-dependency of the phosphorylation.
Figure 5. Low concentrations of AnxA2 (0.1–1 µM) has a stimulatory effect 
on the expression of the c-myc RLuc reporter in an in vitro coupled 
transcription/translation system. The T7-driven transcription of chimera 1A 
[c-myc-5ʹUTR-RLuc-c-myc-3ʹUTR] from a PCR fragment (22 ng/μl). Subsequent 
translation of the construct was performed for 60 min at 30°C in the absence or 
presence of 0.1, 1, 10 or 20 µM of His-AnxA2 as indicated. Aliquots in triplicates 
(60 min) were withdrawn. The results are presented as percentage incorporated 
[35S]-Met, as determined by scintillation counting, relative to the reactions in the 
absence (set at 100%) of His-AnxA2. The results from three independent experi-
ments (n = 3) are shown. The standard deviations are also indicated. Statistical 
significance was determined by the two-tailed Student’s t-test (*p < 0.05).
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4. Discussion
4.1 Annexin A2 interacts with the IRES region of c-myc 
5ʹUTR containing two pseudo-knots in a Ca2+-dependent 
manner
AnxA2 is a multifunctional protein involved in membrane- 
related events as well as RNA-related events and most of its 
functions are regulated by calcium and multiple post- 
translational modifications [1–4,65]. Thus, AnxA2 could be 
regarded as a master regulator, which in response to external 
signalling co-ordinates vesicle and RNA events as shown by its 
family member, AnxA11 [66]. These events are likely to be 
regulated by post-translational modifications such as phosphor-
ylation. Indeed, angiotensin II activation of the AT1a receptor 
stimulates the AnxA2 RNA-binding activity, not by upregulating 
the expression of AnxA2, but by increasing its phosphorylation 
[67]. The phosphorylation site(s) were not identified, but we 
have previously shown that Ser25 phosphorylated and ubiquiti-
nated/sumoylated AnxA2 are enriched in mRNP complexes that 
are not active in translation [50]
AnxA2 is part of mRNP complexes containing c-myc mRNA 
[11,12,14] and other specific mRNAs translated on cytoskeleton- 
bound polysomes [2,13,49]. Other RNA-binding proteins, such 
as Y-box-binding protein (YB), hnRNP K, nucleolin and poly-
(A)-binding protein (PABP), also interact with AnxA2 in mRNP 
complexes, as shown by immunoprecipitation experiments com-
bined with mass spectrometry [14,68]. The poly(A)-tail with its 
bound PABP is important for cap-dependent translation by 
establishing an interaction with eIF4E via eIF4G [69]. This 
‘bridge’ is dispensable for the interaction of the poly(A) tail 
with the c-myc IRES to stimulate translation [70,71]. However, 
it is also known that PABP1 stimulates translation of at least 
certain viral IRES-containing RNAs [72]. Thus, although AnxA2 
interacts with PABP [14], the role that this interaction may play 
in discriminating between cap-dependent and IRES-dependent 
initiation of translation remains unclear.
We have previously identified an AnxA2-binding site in the 
3´UTR of the c-myc [12] and anxA2 [11] mRNAs. 
Furthermore, alignment studies and UV-crosslinking experi-
ments lead us to suggest that a five nucleotide consensus 
sequence, 5ʹ-AA(C/G)(A/U)G, together with higher order 
structures of the 3ʹUTRs, are involved in the interaction with 
AnxA2 [11]. The AnxA2-binding site in the c-myc 3´UTR 
involves the c-myc localization element responsible for its 
transport to the perinuclear region for translation [12,33].
Figure 6. Short-term (1 hr) forskolin treatment increases the expression of p53 while decreasing the expression of c-Myc. Panel A: 1 hr stimulation of PC12 
cells with 20 µM Fsk alone or in combination with a 1 hr pre-treatment with 100 µM EGTA and the effect on the expression of AnxA2, c-Myc and p53. The controls are 
indicated with black columns and are untreated cells with vehicle (DMSO) for Fsk treatment alone. For Fsk treatment with pre-incubation with EGTA, the control cells 
were treated with vehicle and EGTA. Panel B: Representative Western blots of the results shown in Panel A. GAPDH was used as a loading control. Panel C: The effect 
of 1 hr Fsk treatment on the phosphorylation of CREB and the expression of c-Fos. Untreated controls are shown as black columns and Fsk-treated cells with green 
columns. Representative Western blots are shown below the columns. Panel D: The effect of 1 and 2 hr Fsk treatment on the Ser25 phosphorylation of AnxA2. 
Proteins (12 μg) derived from total lysate from PC12 cells were subjected to 4–20% SDS-PAGE and western blot analysis. The results from three independent 
experiments (n = 3) are shown and were normalized to GAPDH. The standard deviations are also indicated. Statistical significance compared to control was 
determined by the two-tailed Student’s t-test (*p < 0.05).
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Here we also identified AnxA2 as a c-myc IRES-binding 
protein (Figs. 1 and 2) and determined the mRNA binding 
site as the c-myc 5´UTR region encompassing nt 196–331 and 
containing one side (strand) of the two pseudo-knots (Fig. 1, 
region 4A). This region also contains the AAGAG consensus 
sequence found in the c-myc 3ʹUTR. The consensus sequence 
is outside the two pseudoknots in the c-myc 5ʹUTR. AnxA2 
can thus be regarded as a member of the c-myc ITAF proteins. 
In addition, we and others have shown that the interaction of 
AnxA2 with c-myc mRNA is Ca2+-dependent (Fig. 2) [12,14].
Interestingly, AnxA2, together with PSF and PTB pro-
teins, has previously been shown to interact with the IRES 
of p53, and to be required for the p53 IRES activity [55]. 
However, while the binding of AnxA2 to the c-myc IRES 
leads to decreased translation of the mRNA in a dose- 
dependent manner (Fig. 4), the binding to the p53 IRES 
leads to increased translation of the corresponding mRNA, 
including both isoforms of p53 [55]. It has been shown in 
the case of p53 mRNA that specific proteins, other than the 
eIF4E-eIF4G-PABP complex necessary for cap-dependent 
initiation of translation, can interact with both UTRs and 
thus regulate p53 mRNA translation [73].
Not only proteins, but also miRNAs and lncRNAs regulate 
the translatability of an mRNA [74]. For example, it has been 
shown that p53 inhibits the expression of c-Myc via miR-145 
[75]. The interaction between the 5´- and 3´UTRs via proteins 
that bind to both regulatory regions adds another layer to the 
complexity. Interestingly, during hypoxia, nucleolin binds the 
3ʹUTR of the collagen prolyl 4-hydroxylase-α(I) mRNA via the 
association with AnxA2, while it binds directly to the 5ʹUTR of 
the same mRNA [68], suggesting that the specific protein 
interactions within the mRNP complexes are highly dynamic.
Several ITAFs, such as hnRNP K and YB, bind the c-myc 
IRES and stimulate the expression of c-Myc [40,45]. Post- 
translational modifications of AnxA2 could alter both its 
interaction with other ITAFs and change the affinity for 
specific RNA sequences. This could change the subset of its 
protein interaction partners and thereby change the interac-
tion with the c-myc IRES. It was found that the phosphor- 
mimicking AnxA2 mutant, AnxA2-S25E, binds RNA with 
higher affinity than wt AnxA2 [76]. Several ITAFs have been 
found to possess both activator and inhibitor properties in 
regulating cellular IRESs [77]. Therefore, the outcome of such 
regulation depends on the composition of the ITAF complex 
bound to the IRES. Thus, it is possible that by binding to the 
c-myc IRES, AnxA2 competes with protein factors that 
enhance the translation of c-myc mRNA via the IRES and/or 
prevent the unfolding of RNA secondary structure necessary 
to initiate translation under circumstances involving an 
increase in Ca2+ levels. For example, it has been shown that 
PSF and AnxA2 share overlapping binding sites on the p53 
IRES and that the interplay between AnxA2, PSF and PTB 
regulates p53 IRES activity. Yet, of these proteins, only the 
binding of AnxA2 to the p53 IRES is Ca2+-dependent [55], as 
observed here for the binding of AnxA2 to the c-myc IRES 
(Figs. 1–2).
However, AnxA2 binds to the pseudo-knot of infectious 
bronchitis virus (IBV) RNA in a Ca2+-independent manner 
and reduces the frameshifting efficiency from IBV pseudoknot 
RNA [78]. At present it is not clear why the binding of AnxA2 
to some mRNAs depends on Ca2+, while its binding to other 
mRNAs does not show this requirement. Post-translational 
modifications of AnxA2 could play a role in its RNA binding, 
since it has been shown that viral IRES activity is not only 
dependent on the recruitment of proteins, but also relies on 
the post-translational modifications of the recruited proteins 
[79]. Ser25 phosphorylation of AnxA2 changes its conforma-
tion to the open state, which does not need Ca2+-to bind RNA 
[50,80]. It also leads to increased mRNA binding [50,76], as 
shown by the results obtained with the phosphor-mimicking 
S25E-AnxA2 (discussed in [4]). Thus, in the absence of suffi-
ciently high concentrations of Ca2+, Ser25 phosphorylation, 
possibly combined with other post-translational modifica-
tions, may regulate the binding of AnxA2 to RNA. It has 
been shown that the S25E mutation also increases the Ca2+- 
independent binding of AnxA2 to G-actin [76].
4.2 Annexin A2 modulates the translation of the c-myc 
reporter in the RRL
The conventional nuclease-treated RRL cell-free system is 
ideal for our purposes, since it lacks endogenous AnxA2 
[81] and has low protease activity [82]. Furthermore, it dis-
plays high translational efficiency, which is an important 
property when studying the effect of inhibitors on translation. 
Consequently, the RRL system has been used in numerous 
studies. For example, by using chimeric c-myc reporter 
mRNAs, this system was employed to show that hnRNP 
C enhances the translation of c-myc mRNA [43]. Nanbru 
and co-workers used the RRL to translate a reporter protein 
from both the CUG and AUG codons in the 5ʹUTR of human 
c-myc mRNAs transcribed from the P0, P1, and P2 promo-
ters [26].
Our first aim was to identify the AnxA2-binding site in the 
c-myc mRNA. That explains why we used the P1 transcript, 
since our preliminary results indicated that the AnxA2- 
binding site is present in a c-myc exon 1 transcript. P2 is 
the predominant transcription start site, giving rise to 75–90% 
of c-myc mRNAs, while 10–25% of c-myc transcripts are 
generated from the P1 start site. As the AnxA2-binding site 
turned out to lie within the IRES, we decided to use mono-
cistronic chimeric c-myc reporter mRNAs. It has been specu-
lated that overexpression of bicistronic mRNAs using viral 
promoters may compromise the apparent efficiency of the 
c-myc IRES [35] since ITAFs may become limiting under 
these conditions. Moreover, it has been shown that specific 
subsets of RNA-binding proteins often operate in concert, 
forming distinct regulatory complexes depending on intracel-
lular conditions. Although our chimeric constructs are tran-
scribed from the T7 promoter, the use of equal molar 
amounts of monocistronic chimeric mRNAs with and without 
the AnxA2-binding or ribosomal docking site regions of the 
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c-myc IRES, and subsequent comparison of their properties, 
partly overcame this problem. However, a point of concern 
could be that AnxA2 acts in concert with other ITAFs and 
these factors may become limiting.
Since AnxA2 binds to region 4A of the IRES of the chi-
meric c-myc mRNA (Fig. 1), we initially deleted only this 
region in the mRNA (Fig. 4). To our surprise, the inhibitory 
effect of AnxA2 on the translation of this chimeric mRNA 
(chimera 1B) was only slightly reduced as compared to the 
chimeric c-myc mRNA containing full-length 5ʹUTR (Fig. 4, 
chimera 1A). Apparently, since AnxA2 bound to both regions 
2 and 4 of c-myc 5ʹUTR with higher affinity than to region 4A 
alone, a new version of the chimeric c-myc mRNA (chimera 
1D) was produced by seamless cloning, this time lacking both 
regions 4A and region 4B, the latter harbouring the ribosomal 
docking site and the two intact pseudo-knots. This deletion 
totally abolished the effect of AnxA2 on the translation of the 
chimeric c-myc mRNA (Fig. 4), indicating that the protein 
may interact with protein factors associating with the riboso-
mal docking site on the IRES or interfere with the formation 
of the initiation complex. For example, it has been shown that 
AnxA2 interacts with receptor for activated C kinase 1 
(RACK1) [83], a ribosome-associated protein implicated in 
the regulation of viral IRES activity [84]. Furthermore, several 
ribosomal proteins of both the small and the large ribosomal 
subunits were found to interact with AnxA2 [14], offering the 
possibility that AnxA2 interacts directly with the ribosome.
Subsequently, to investigate the role of the ribosomal dock-
ing site, only region 4B was deleted from the 5´UTR of the 
chimeric c-myc mRNA (chimera 1C) (Fig. 4). The translation 
of this chimeric mRNA was inhibited by AnxA2 in the same 
manner as chimeras 1A and 1B (Fig. 4), although not to the 
same extent, indicating that our assumption was correct in 
that region 4A is involved in the binding of AnxA2 leading to 
its subsequent inhibitory effect on translation. It should be 
noted that when only region 4B of the c-myc IRES is deleted, 
it has a great impact on the translational efficiency of the 
reporter by lowering it by about 50% (Fig. 4) indicating its 
function as a ribosomal docking site.
Possible explanations for these results, could be that when only 
region 4A is deleted, AnxA2 may still interact with the ribosome, 
perhaps due to the AnxA2-binding site possibly extends slightly 
into region 4B. When region 4B is deleted, the main consequence 
would be that the translational efficiency of the mRNA is reduced 
due to the lack of the ribosomal docking site, but AnxA2 may still 
provide a sterically hindrance for a ribosome scanning from the 5 
´end. It is also possible that the binding of AnxA2 to region 4A 
combined with the deletion may result in the formation of inhibi-
tory sequences in the c-myc 5´UTR. When both regions 4A and 4B 
are deleted, AnxA2 has lost its binding site and cannot interact with 
the ribosome or proteins factors on the ribosomal docking site. It 
cannot be ruled out entirely that binding of AnxA2 to the 3´UTR of 
c-myc affects the events taking place at the c-myc 5´UTR. However, 
preliminary data indicate that domain IV of AnxA2 inhibits in 
a dose-dependent manner the translation of a c-myc chimera only 
containing the c-myc 5´UTR in front of the reporter and no 3´UTR 
(data not shown).
Interestingly, the time-course curve of translation for the 
chimeric c-myc mRNA lacking region 4 of the c-myc 5ʹ-UTR 
indicates that translation reaches a steady state after 30 min. 
Furthermore, translation of this construct has a faster initial 
phase, while at 60 min it only amounts to about 80% of that of 
full-length chimeric c-myc mRNA (Fig. 4). This could be due to 
exhaustion of energy supply. Another more likely possibility is 
that the deletion of the ribosomal docking site hampers the 
binding of ribosomes to internal regions of the 5´UTR. This 
possibility is corroborated by the finding that deletion of the 
ribosomal docking site in the IRES lowers the translational 
efficiency of the chimeric c-myc mRNA by about 50% compared 
to the chimera containing the full-length 5´UTR (Fig. 4). In the 
present study, full translational activity of the chimeric c-myc 
reporter mRNA was only observed when the two c-myc UTRs 
were present, but not when the c-myc 5´UTR was exchanged 
with that of the β2-µglobulin mRNA. This also decreased the 
translatability of the mRNA by about 50% (Fig. 3). Considering 
the effect of deleting the ribosomal docking site (region 4B) from 
the IRES (Fig. 4), this suggests that this could be mainly due to 
the absence of an IRES in the β2-µglobulin mRNA.
To explore whether the effects of AnxA2 on the translation 
of the c-myc chimeric mRNAs are specific, it was necessary to 
include various negative control proteins that do not bind to 
mRNA and therefore should have no effect on translation. We 
have constructed a mutant form of the full-length AnxA2, 
which does not bind RNA [10,58] and thus could be used as 
a negative control in the RRL. The helices C and D of domain 
IV of AnxA2 harbour two well-exposed regions, i.e. 
307KKK309 in helix C and 315YYYIQQD321 in helix D, which 
together with Gly311 and Lys312 in the loop between these 
helices, provide the sites for interaction with a bulky RNA 
target. Thus, the non-RNA-binding mutant full-length AnxA2 
harbours the following mutations: K307S-K308S-K309S- 
K312S-Y316S-Q320S [10]. In addition, BSA was included as 
another non-mRNA-binding control protein. Indeed, the con-
trol assays confirmed that the effects exerted by AnxA2 are 
specific, since neither of these proteins inhibited the transla-
tion of the chimeric full-length c-myc mRNA (1A) containing 
the IRES (Fig. 4). These results argue against a possible unspe-
cific inhibitory effect of AnxA2 on the translation of the RLuc 
reporter.
At present, we cannot explain the stimulatory effects on 
translation of chimera 1A at low concentrations of AnxA2 on 
the translation (Fig. 5). However, we have observed the same 
effect of AnxA2 on its cognate mRNA (results not shown). It 
is possible that this is related to the interaction with other 
proteins and as the concentration of AnxA2 increases, the 
stoichiometry of complex formation with specific ligands 
changes. This is certainly interestingly to pursue in future 
studies. Post-translational modifications could also be 
involved.
4.3 The cellular correlation between the expressions of 
Annexin A2 and c-Myc
Cellular control and regulation of protein expression is 
important and can be exerted at several levels. RNA-binding 
proteins play an important role at the level of mRNA trans-
port and translation [85]. Here we show that lower levels of 
AnxA2 apparently increase the translation of the c-myc 
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reporter while higher concentrations of AnxA2 inhibit trans-
lation (Figs. 4 and 5), suggesting an inverse relationship 
between the cellular levels of the two proteins. We observed 
that AnxA2 expression is very high in MCF10A, relatively 
high in MDA231 and very low in MCF7 cell lines 
(Supplementary Fig. S1). Others have reported that c-Myc 
levels are high in MCF7, lower in MDA231 and very low in 
MCF10A cell lines [86], corroborating this assumption. 
Furthermore, c-Myc is overexpressed in the earliest phases 
of prostate cancer [87] when the expression of AnxA2 is very 
low [88]. HepG2 is a human cell-line derived from hepato-
blastoma. These cells express c-myc mRNA constitutively, and 
do not contain detectable levels of AnxA2 [89,90]. Thus, these 
findings could provide additional support for the present 
results, addressing the role of AnxA2 in the regulation of 
c-Myc expression.
It is unlikely that the correlation between the c-Myc and 
AnxA2 protein levels in vivo is as simple as the given examples 
suggest, since i) the level of c-Myc expression can be regulated 
at initiation of translation both by a cap-dependent and an 
IRES-dependent mechanism [35], ii) AnxA2 binds the c-myc 
mRNA only in the presence of high Ca2+ concentrations, per-
haps locally (if not phosphorylated on Ser25), iii) AnxA2 binds 
both to the c-myc 3´UTR and the 5´UTR, iv) the effect may be 
related to the AnxA2/mRNA (specific mRNAs binding to 
AnxA2) ratio and v) post-translational modifications are likely 
to be involved. As AnxA2 appears to harbour only one RNA- 
binding site [10], it may bind as a homodimer or as a monomer 
in complex with different ligands if bound simultaneously to 
both UTRs. Another possibility is that AnxA2 does not bind to 
both UTRs simultaneously.
It is difficult to achieve a detailed understanding regarding 
the molecular mechanisms of cellular IRESs, since no in vitro 
system totally recapitulates the function of these elements 
[91]. Since AnxA2 is a multifunctional protein and RNA- 
binding is only one of its many cellular functions, the use of 
in vitro translation systems provides a very important 
approach for gaining insight into its role in RNA related 
processes before starting with cell lines with many cellular 
processes taking place simultaneously.
Fsk stimulation of HUVEC cells leads to a redistribution of 
AnxA2 from the cytosol to the plasma membrane. 
Furthermore, this stimulation resulted in decreased Ser11 
phosphorylation of AnxA2, leading to its subsequent binding 
to S100A10 and participation in secretion [92], while we 
found that Ser25 phosphorylation of the protein was increased 
by Fsk treatment (Fig. 6). Ser25 phosphorylation of AnxA2 
was highly elevated, in particular after 2 h treatment with Fsk. 
By contrast, Fsk stimulation of PC12 cells apparently gave rise 
to a modest increase in the expression of AnxA2 while slightly 
decreasing the expression of c-Myc (Fig. 6). Fsk treatment 
increased the expression of p53, which could be abolished by 
EGTA pre-treatment (Fig. 6). The EGTA treatment chelates 
extracellular Ca2+, since the stimulatory effect of Fsk is depen-
dent on an influx of extracellular Ca2+ [93]. Thus, on one 
hand Fsk may trigger the release of AnxA2 in secretory 
granules together with its partner S100A10 [92]. On the 
other hand, increased Ser25 phosphorylation together with 
other post-translational modifications could lead to 
participation of AnxA2 in the translational silencing of spe-
cific mRNAs as pSer25AnxA2 partially colocalises with the 
P-body marker GW182 [50]. The increased binding of AnxA2 
to RNA after angiotensin II activation of the AT1a receptor 
was due to increased phosphorylation of the protein and not 
to an increase in the expression of AnxA2 [67]. Thus, it is 
likely that Ser25 phosphorylation is important for the effects 
we observe in the cell system. However, due to the multi-
functionality of AnxA2 it is not easy to discern between the 
individual functions of the protein.
The regulation of the binding of AnxA2 to RNA is not 
straightforward. The wild-type AnxA2 binds to RNA in the 
presence of Ca2+ [10]. However, when AnxA2 is Ser25 phos-
phorylated, the protein can bind RNA in the absence of Ca2+ 
[76]. Then the protein is in its open state [80] and presumably 
in a state where the RNA-binding site in domain IV becomes 
more accessible. Thus, the effects of the Fsk treatment of 
PC12 cells were not clear-cut but indicated tendencies. Most 
importantly, the reduction in c-Myc expression and the 
increase in AnxA2 expression by Fsk could be reversed by 
EGTA treatment (Fig. 6).
As mentioned above, several ITAFs bind the c-myc IRES 
and normally promote IRES-dependent translation, while the 
Ca2+-dependent binding of AnxA2 to the c-myc IRES inhibits 
translation. Ca2+-signalling is remodelled in some cancers 
exerting effects on cell proliferation, invasion, propensity to 
apoptosis, multidrug resistance and the tumour microenvir-
onment [94]. Ca2+-fluxes also operate during mitosis [95] 
and in the synapse [96]. It is possible that under these 
circumstances a Ca2+-dependent switch may operate between 
cap-dependent and IRES-dependent mode of translation 
initiation. AnxA2 could mediate this switch that triggers 
the response to elevated Ca2+ levels, most likely in concert 
with other ITAFs. Future investigations should address in 
detail the multifunctional nature of AnxA2, whose distinct 
functions are regulated by its post-translational modifica-
tions and ligand interactions [2] and also how this affects 
the regulation of the c-myc IRES. Since AnxA2 binds to both 
the 5ʹUTR and the 3ʹUTR, it is possible that inhibition of 
translation is coupled to mRNA transport. Furthermore, 
since AnxA2 binds to endosomes and trafficking of mem-
branes and mRNAs are interconnected processes [97], it is 
tempting to speculate that AnxA2 may co-ordinate transport 
of vesicles and specific mRNAs in response to extracellular 
signals.
5. Conclusions
AnxA2 binds to the IRES of c-myc 5´UTR and modulates the 
translation of the mRNA in the presence of Ca2+. This opens 
the interesting possibility that AnxA2 acts as a Ca2+- 
dependent switch between cap-dependent and IRES- 
dependent translation of c-myc mRNA.
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